Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
As Medicare announced a fresh set of drugs selected for its price-setting process on Friday under the Inflation Reduction Act ...
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
Given multiple recent news articles saying that pharmacies are struggling amid problems caused by pharmacy benefit managers (PBMs) , you might not be surprised by these examples. However ...
Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback